Background: Vitamin D plays a key role in calcium homeostasis and contributes to the regulation of the immune system. Furthermore, vitamin D deficiency has been reported to be associated with autoimmune diseases (AIDs), especially with multiorgan AIDs. Various multiorgan AIDs may be different based on the vitamin D status. This study aims to investigate the serum 25-hydroxyvitamin D (25(OH)D) levels in patients with different common multiorgan AIDs. Methods: A total of 295 patients with multiorgan AIDs treated in our hospital from January 2012 to September 2018 were recruited, including 137 cases of rheumatoid arthritis (RA), 85 cases of systemic lupus erythematosus (SLE), 32 cases of Sjögren's syndrome (SS) and 41 cases of mixed connective tissue disease (MCTD); 47 apparently healthy individuals were also recruited as controls. The serum 25(OH)D levels in patients with different multiorgan AIDs were measured with Roche electrochemiluminescence immunoassay and statistically analyzed the proportion of patients with normal, insufficiency and deficiency in 25(OH)D levels in different multiorgan diseases. The 25(OH)D levels of different multiorgan AID groups and healthy controls were also compared. Results: Incidences of 25(OH)D deficiency in the RA, SLE, SS and MCTD groups were 21.2%, 35.3%, 25.0% and 22.0%, respectively, with significant inter-group differences (p < 0.05). The incidence in the SLE group was higher than in the RA, SS and MCTD groups, indicating severe 25(OH)D deficiency in patients with SLE. Significant inter-group differences (p < 0.05) were detected in the serum 25(OH)D levels in different multiorgan AID groups and in the healthy control group. Further pairwise comparison found a significantly higher level of 25(OH)D in the healthy control group than in the SLE, SS, RA and MCTD groups (p < 0.05). Moreover, the 25(OH)D status in the SLE group was significantly lower than that in the SLE, SS, RA and MCTD groups (p < 0.05). Conclusions: Serum 25(OH)D deficiency and a low 25(OH) D status are commonly seen in patients with different multiorgan AIDs compared to healthy controls, warranting vitamin D supplementation. Severe 25(OH)D deficiency and a lower 25(OH)D status were found in patients with SLE.
Introduction
Autoimmune diseases (AIDs) were considered to be rare but have now been shown to affect 3-5% of the population, with nearly 100 distinct types of classification, some of which are organ specific, such as primary biliary cirrhosis (PBC), and some of which reflect a variety of immunological dysfunctions involving multiple organs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS) and mixed connective tissue disease (MCTD). Multiorgan AIDs are usually accompanied by the dysfunction of multiple organs. Most importantly, their effects on mortality and morbidity are significant [1] .
Recently, it has been reported that T cells play an important role in AIDs and could balance the immune system. One of the most significant findings is that active vitamin D and its analogs can modify the immune state mediated by T cells [2] . This function has been proved in various animal models of multiple AIDs. Nevertheless, vitamin D levels in patients with various AIDs are found to be significantly decreased [3] , suggesting a possible connection between vitamin D and the pathogenesis of many AIDs. It is also suggested that vitamin D, as a new immunomodulator, may be added to treatment regimens of multiple organ AIDs.
Vitamin D is a group of fat-soluble steroid derivatives, which is a hormone primarily produced in the skin that travels to the liver initially and then to the kidneys, where 1,25-dihydroxy-vitamin D is formed under the activities of hepatic 25-hydroxylase and renal 1α-hydroxylase. The active form of vitamin D (1,25-dihydroxy-vitamin D) has binding vitamin D receptors (VDRs) that are expressed in the immune system, and is a potent immunomodulator that helps maintain immune homeostasis [4, 5] . VDRs exist in most organ cell surfaces, including brain, heart, pancreas, skin and gastro-intestinal tracts. Previous studies have indicated the role of vitamin D in the pathogenesis of various diseases [6] [7] [8] . Being a major form of the circulating vitamin D, 25-hydroxyvitamin D (25(OH)D) has a half-life of approximately 2 weeks, making the serum level of 25(OH)D the most effective measurement in evaluating the vitamin D status [9] .
Studies have shown that the majority of patients with SLE, RA and SS have 25(OH)D deficiency when compared with controls [10] [11] [12] , but not when compared mutually. This study aims to investigate the serum 25(OH)D levels in patients with the common multiorgan AID, to evaluate the level of differences among these diseases and to provide evidence supporting vitamin D supplementation.
Materials and methods

Patients
This retrospective study included a total of 295 eligible patients with multiorgan AIDs treated in our hospital between January 2012 and September 2018, including 137 cases of RA, 85 cases of SLE, 32 cases of SS and 41 cases of MCTD. All subjects were treatment naïve. In order to prevent osteoporosis, patients who took calcium and vitamins were unavoidable and hence not excluded. Fortyseven apparently healthy individuals were also recruited as controls. Anthropometric, demographic and clinical data collected from the electronic medical records or clinical interview included age, sex, race, weight, height, history of chronic disease and medications in use. The present study was approved by the Research Ethics Committee of the First Affiliated Hospital of Nanjing Medical University, and all patients provided written consent prior to study enrollment.
Samples
Peripheral blood samples (3 mL) from each subject after fasting for 12-14 h were collected by venipuncture into a vacuum tube. After centrifuging at 3000 r/min for 5 min, the supernatant serum was extracted for measuring 25(OH)D. The Roche Cobas e 601 electrochemiluminescence analyzer system (Roche Diagnostics GmbH, Mannheim, Germany) and corresponding Roche Cobas Vitamin D total assay reagent (Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer's instructions, were used for this measurement. For each test batch, highand low-value quality control samples were used.
The status of vitamin D
Currently, no optimal levels of 25(OH)D have been definitively determined. Vitamin D deficiency is mostly defined as serum 25(OH)D lower than 25 nmol/L. Vitamin D insufficiency and normal vitamin D are defined as serum 25(OH) D between 25 and 50 nmol/L and higher than 50 nmol/L, respectively [13] .
Statistical analysis
STATA software 12.0 (StatCorp, College Station, TX, USA) was used for all statistical analyses. The Kruskal-Wallis non-parametric test was used to compare the 25(OH)D levels between the multiorgan AID groups and healthy controls. The Mann-Whitney test was used to compare the vitamin D status of any two groups. Ratio comparison was used to compare the incidence of vitamin D deficiency in multiorgan AID groups. The level of significance was set at p < 0.05.
Results
Demographics and clinical characteristics of multiorgan AID patients
The final count of multiorgan AID patients consisted of 137 cases of RA, 85 cases of SLE, 32 cases of SS and 41 cases of MCTD. As shown in Table 1 , most of them were females. The proportion of females in the RA, SLE, SS and MCTD groups was 84.0%, 96.5%, 90.6% and 72.3%, respectively. All the patients were of Chinese descent. Several clinical characteristics of the patient groups and the healthy control group, including body mass index, current smoking, diabetes mellitus, hypertension, hypercholesterolemia and history of cardiovascular disease, are also listed in Table 1 .
Distribution of 25(OH)D levels in different multiorgan autoimmune disease groups
As shown in Table 2 , the proportion of subjects with normal 25(OH)D levels in the RA, SLE, SS and MCTD groups was 31.4%, 23.5%, 37.5% and 17.0%, respectively. Incidences of 25(OH)D deficiency in these groups were 21.2%, 35.3%, 25.0% and 22.0%, with significant inter-group differences (p < 0.05). The incidence in the SLE group was higher than in the RA, SS and MCTD groups, indicating severe 25(OH) D deficiency in patients with SLE.
Comparison of serum 25(OH)D levels in different multiorgan autoimmune diseases
As shown in Figure 1 , significant inter-group differences (p < 0.05) were detected in the serum 25(OH)D levels in different multiorgan AID groups and in the healthy control group. Further pairwise comparison found 25(OH)D to be significantly higher in healthy controls than in the SLE, SS, RA and MCTD groups (p < 0.05). Moreover, the 25(OH)D status in the SLE group was significantly lower than that in the SS, RA and MCTD groups (p < 0.05). The incidence in the SLE group was higher than in the RA, SS and MCTD groups. 
Discussion
Vitamin D deficiency is found in patients with various diseases, especially AIDs [14, 15] . When compared with organspecific AIDs, multiorgan AIDs are more harmful to health [16] . However, to the best of our knowledge, there is no available report describing the vitamin D deficiency status in patients with various multiorgan AIDs. In this study, we performed the first preliminary analysis of serum 25(OH) D levels in hospitalized patients with common multiorgan AIDs. The serum 25(OH)D was measured by Roche "Vitamin D total" ECLIA systems; the advantage of this assay from the previous "Vitamin D3" assay is that this system measured 25(OH)D 2 and D 3 instead of only 25(OH) D 3 [17] . Multiple factors can affect the vitamin D status, including but not limited to sunlight exposure, latitude, season, age, gender and nutrition in the diet. At a latitude of 31° N, there are fewer hours of sunlight in Nanjing, leading to a limitation in vitamin D synthesis by sunlight. Moreover, some patients such as those in the SLE group should avoid sunlight exposure [18] ; therefore dietary supplement is an alternative in such cases. Food rich in vitamin D including breast milk, egg yolk, animal livers (e.g. cod liver oil) and fatty marine fish (e.g. salmon) should be recommended. If not, it will result in vitamin D deficiency.
In our study, incidences of 25(OH)D deficiency in patients with RA, SLE, SS and MCTD were 21.2%, 35.5%, 25.0% and 22.0%, respectively, indicating varying degrees of concomitant vitamin D deficiency in all these four AIDs, which is in accordance with previous studies [3] . This result revealed substantially lower serum 25(OH)D levels in patients with multiorgan AIDs in Nanjing. The incidence in the SLE group was higher than in the RA, SS and MCTD groups. One possible explanation for more severe vitamin D deficiency in SLE patients is the universal recommendation that these patients should avoid sunlight exposure [19] . Moreover, with a relatively small number of subjects with SS or MCTD in this study, there may be some bias in the results. In further studies, more patients with SS or MCTD would be recruited.
Our study is the first one reporting the distribution of serum 25(OH)D levels in patients with common multiorgan AIDs in the Nanjing area. In this study, significant inter-group differences (p < 0.05) were detected in serum 25(OH)D levels in different multiorgan AIDs and in the control group. This indicates that vitamin D deficiency in multiorgan AIDs is widely prevalent. Further, pairwise comparison found a significantly higher level of 25(OH)D in the control group than in other multiorgan autoimmune groups. In this study, vitamin D deficiency is proved to be a common phenomenon in all these disease groups. Meanwhile, 25(OH)D level monitoring in the treatment of AIDs is important for adjusting 25(OH)D supplementation. It is reported that vitamin D supplementation has a preventive effect on AIDs by immunomodulation [20] and can be added to the therapeutic regimen of AIDs, especially SLE.
Given the limitations of the small sample size, only four types of diseases being incorporated and fewer cases with two diseases reported in this study, further studies with more types of diseases and more subjects are needed to improve this analysis and provide more evidence in instructing vitamin D supplementation in patients with AIDs.
In conclusion, serum 25(OH)D deficiency and low 25(OH)D status are commonly seen in patients with different multiorgan AIDs when compared with healthy controls. Furthermore, severe 25(OH)D deficiency and a lower 25(OH)D status were found in patients with SLE.
